



Machine Learning and Mechanistic Modeling for the prediction of Overall Survival on the basis of 1st line Tumor Dynamics in Head and Neck Squamous Cell Carcinoma

Kevin Atsou, Anne Auperin, Joël Guigay, Sébastien Salas, Sébastien Benzekry

► To cite this version:

Kevin Atsou, Anne Auperin, Joël Guigay, Sébastien Salas, Sébastien Benzekry. Machine Learning and Mechanistic Modeling for the prediction of Overall Survival on the basis of 1st line Tumor Dynamics in Head and Neck Squamous Cell Carcinoma. Colloque Science numériques et intelligence Artificielle pour la Santé, AMU, Nov 2021, Marseille, France. hal-03467230

HAL Id: hal-03467230

<https://inria.hal.science/hal-03467230>

Submitted on 6 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Machine Learning and Mechanistic Modeling for the prediction of Overall Survival on the basis of 1st line Tumor Dynamics in HNSCC

K. Atsou¹, A. Auperin², J. Guigay³, S. Salas^{1,4}, S. Benzekry¹

¹COMputational pharmacology and clinical Oncology Team, Inria Sophia Antipolis - Méditerranée, Cancer Research Center of Marseille, Inserm, CNRS, Aix Marseille University, Marseille, France.

²Biostatistical and Epidemiological Division, Institut Gustave Roussy, Villejuif, France.

³Clinical Oncology, Centre Antoine Lacassagne, Nice, France

⁴Clinical Oncology, Hôpital Timone, Aix-Marseille University, Marseille, France.

BACKGROUND

- Prediction of **Overall Survival** and **Response to 2nd line** is a **major challenge** in treatment of HNSCC
- Tumor kinetics during first line** may provide interesting **predictive metrics** for Overall Survival

OBJECTIVES

- Propose the best **mathematical model** for the description of the longitudinal measurement of the patients individual SLDs (Sum of the Largest Diameters)
- Predict the **Overall Survival** using the kinetic data of first line and some baseline data

MATERIAL AND METHODS¹

Clinical data

- EXTREME (cetuximab, 5-FU, platinum) vs TPEX (cetuximab, docetaxel, platinum)
- Phase 2 clinical trial**
- 528 patients** enrolled (263 (TPEX) and 265 (EXTREME)).

Tumor Growth Inhibition (TGI) models²:

Tumor Growth model with treatment effect

$$SLD(t) = SLD_0 e^{-KS/\lambda(1-e^{-\lambda t}) + KGt}$$

Biexponential model with resistant cells

$$SLD(t) = SLD_0 (\alpha e^{KGt} + (1 - \alpha)e^{-KSt} - 1)$$

Biexponential model

$$SLD(t) = SLD_0 (e^{KGt} + e^{-KSt} - 1)$$

Nonlinear Mixed Effects Modeling (NLMEM)

$$y_j^i = f(t_j^i; \theta^i) + e_j^i$$

observation of individual i at time t_j^i

structural model

error model

$$\theta^i = \mu \exp(\eta^i)$$



$$\eta^i \sim \mathcal{N}(0, \omega)$$

μ fixed effects, η^i random effects

$$e_j^i = (\sigma_1 + \sigma_2 f(t_j^i; \theta^i)) e_j^i$$

$$e_j^i \sim \mathcal{N}(0, 1)$$



combined error model



Kinetic signature



Baseline Features

MACHINE LEARNING



RESULTS

The Biexponential model provides the best Fit (AIC and identifiability)³





Prediction of the Overall Survival


Best performance for Random Survival Forest (C-index= 0.7)

On the training set: 0.7

On the test set: 0.67



KG is the most important parameter for predicting OS



Tumor Kinetic Parameters Outperform All Others

CONCLUSION AND PERSPECTIVES

- A **mechanistic** mathematical model was able to fit the **clinical data** of SLD measurements in a HNSCC clinical trial
 - Mechanistic modeling and Machine learning algorithms were combined to predict **Overall Survival**
 - Predictive power is **only modest so far** but only the SLD measurements was considered
- ==> include **more features** and model **individual lesions kinetics**

References

- S. Benzekry, Artificial Intelligence and Mechanistic Modeling for clinical Decision Making in Oncology, Clinical Pharmacology and Therapeutics (2020)
- R. Bruno, F. Mercier, L. Claret, Evaluation of Tumor size Response Metrics to predict Survival in Oncology Clinical Trials, Clinical Pharmacology and Therapeutics (2014)
- Monolix Version 2018R2. Lixoft SAS (2018)